Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
Share
ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by acting on brain circuits that regulate energy and metabolism. In addition to the clinical trial results, ENT-03 is effective as a monotherapy and has an additive effect in combination with GLP1 agonists in animal models. ENT-03 also demonstrates durable weight loss and glucose and insulin normalization after therapy cessation.
'Our first-in-human study has demonstrated that ENT-03 is safe and very well tolerated and showed positive trends in both weight loss and insulin sensitivity that are consistent with what we have seen in preclinical in vivo studies,' said Richard Larson, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Metabolics Pharma. 'We are planning a Phase 1b study to evaluate dosing regimens, which we expect to initiate in the second half of 2025.'
The Phase 1a clinical trial was a single ascending dose study evaluating seven dose cohorts of ENT-03 in healthy obese subjects and obese subjects with type 2 diabetes (T2D). ENT-03 was administered subcutaneously (SQ) at six different doses. The primary endpoint was safety and tolerability and pharmacokinetic data. Secondary endpoints included fasting blood glucose, fasting insulin, lipid levels, and change in body weight at 7 days. More information can be found on clinicaltrials.gov.
ENT-03 was very well tolerated and efficacy endpoints showed trends toward weight loss at higher doses for both obese and obese/T2D subjects, along with improvement in insulin sensitivity.
About Metabolics Pharma
Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity, type 2 diabetes, and MASH. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit www.metabolicspharma.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
30 minutes ago
- Associated Press
Rachelle Ramiro Breaks Down Energy, Clarity, and Control on The Health is A Skill Podcast with Todd Vande Hei
08/19/2025, Beverly Hills California // KISS PR Brand Story PressWire // On this new episode of Health is a Skill, host Todd Vande Hei welcomes Rachelle Ramiro, founder of CEO2 Health, for a revealing conversation about how a life-changing diagnosis reshaped her relationship with time, energy, and well-being. Diagnosed with multiple myeloma in her early 30s, Ramiro chose to take a proactive, multi-dimensional approach to healing. Speaking from inside a hyperbaric oxygen chamber, she details how early detection, unconventional therapies, and consistent recovery practices helped her normalize her labs, regain vitality, and stay fully engaged in both work and life. Key topics from the conversation include: Ramiro says, 'At one point, I couldn't even walk because of the pain. But after starting therapies like exosomes, I felt hopeful, mobile, and even joyful. I'm walking in Italy today because I chose to invest in my wellness.' The discussion also explores the growing role of mobile wellness: CEO2 Health now delivers hyperbaric oxygen therapy across homes, offices, events, and luxury spaces through portable chambers and custom installations. To learn more about personalized recovery and mobile hyperbaric therapy, visit About Health Is a Skill Health is a Skill is a Los Angeles-based podcast hosted by Todd Vande Hei, CEO of Stark Health. Each episode blends scientific insight, personal stories, and actionable habits to show how optimizing healthspan can transform every decade of life. Media Communications: [email protected]
Associated Press
30 minutes ago
- Associated Press
PufCreativ Launches PufCreativ Cares to Expand Charitable Impact Across Cannabis and Wellness, Celebrating Millions Raised for Good Causes
Leading Creative Agency to Partner with HoliHub for National Recovery Month in September DENVER, COLORADO - August 19, 2025 ( NEWMEDIAWIRE ) - PufCreativ, a full-service cannabis marketing agency blending award-winning creative with data-driven strategy to empower brands shaping the future of cannabis and wellness, announced today the launch of PufCreativ Cares, the company's charitable arm uniting all of its giving initiatives under one banner. From its founding in 2017, PufCreativ has integrated philanthropy into its business model, helping to raise more than $12 million for nonprofits across the cannabis, wellness, and advocacy spaces. Through PufCreativ Cares, the company will expand its reach and inspire more industry peers to contribute to causes that matter, particularly those supporting equity, wellness, and community impact. Past charitable partners include Companies Doing Good, Cannabis Impact Fund, and the Colorado Coalition Against Sexual Assault. This September, in honor of National Recovery Month, PufCreativ is partnering with HoliHub, a Denver-based, peer-run nonprofit redefining recovery through inclusive, community-led healing. HoliHub's programs combine group support, one-on-one counseling, and a wide range of holistic services that are all delivered through an accessible, sliding-scale model. In under a year, HoliHub has supported more than 500 individuals and achieved an 83% return rate, signaling deep community trust. 'This partnership with HoliHub is a full-circle moment for me and PufCreativ,' said CEO John Shute. 'Over the years, I've seen friends and family struggle with opiate addiction, and those experiences inspired me to pursue a career in cannabis more than a decade ago. Founding PufCreativ and launching PufCreativ Cares allows me to combine my passion for the industry with a mission to uplift communities, and supporting accessible, inclusive recovery programs is a natural extension of that commitment.' Funds raised during the Recovery Month campaign will go directly toward expanding HoliHub's services, building bridges between recovery and alternative wellness communities, and championing inclusive, stigma-free pathways to healing. 'Our partnership with PufCreativ represents a vital shift in how we talk about recovery, moving beyond stigma to a place of understanding and compassion,' said Shimi Mermelstein, Founder and Executive Director of HoliHub. 'Recovery is diverse, complex, and deeply personal. Together, we're opening the door for all voices to be heard, honored, and supported. That is true progress.' PufCreativ's clients include licensed dispensaries, product brands, multi-state operators, nonprofits, and advocacy groups, as well as health and wellness brands entering the alternative medicine space. The company also works with women-led, BIPOC (Black, Indigenous, and people of color)–led, LGBTQIA (lesbian, gay, bisexual, transgender, queer, intersex, and asexual)–led, and equity-focused teams, along with industry service providers, consultants, and legal professionals. To learn more about PufCreativ Cares, visit About PufCreativ PufCreativ is a full service cannabis marketing agency rooted in community, creativity, and cultural authenticity. We operate at the intersection of bold visual storytelling and high-impact performance strategy, helping brands not only define who they are - but grow, convert, and thrive in a complex and evolving industry. Our team merges award-winning creative with cannabis-specific marketing systems that drive measurable results. From day one, we've been committed to building brands with heart, but we also know how to attract the right audience, increase revenue, and retain loyal customers through refined, compliant, and data-backed strategies. We work with cannabis brands, dispensaries, nonprofits, advocacy groups, and ancillary businesses that are reshaping the future of the industry. Our services span brand identity, content creation, packaging, digital strategy, web development, paid media, retention marketing, and performance analytics. Since its founding in 2017, PufCreativ has embedded philanthropy into its mission, raising more than $12 million for nonprofits across cannabis, wellness, and advocacy. Through PufCreativ Cares, the company centralizes its charitable efforts, amplifying impact and encouraging industry peers to support meaningful causes. At our core, we are creative problem solvers with a performance mindset. Visit to learn more. Media Contact Nicole Farah Americana Communications [email protected] View the original release on
Yahoo
31 minutes ago
- Yahoo
Is Wall Street Bullish or Bearish on Thermo Fisher Scientific Stock?
With a market cap of $155.6 billion, Thermo Fisher Scientific Inc. (TMO) stands as a global leader in serving science, providing cutting-edge technologies, services, and solutions that drive research and enhance healthcare. The Waltham, Massachusetts-based company operates through four core segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. Shares of TMO have underperformed the broader market, dropping 19% over the past year and 6% in 2025. In comparison, the broader S&P 500 Index ($SPX) has gained 16.4% over the past 52 weeks and 9.7% on a YTD basis. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Powell, Trump Talks and Other Can't Miss Items this Week 'My Kid Will Never Ever Be Smarter Than an AI': OpenAI's Sam Altman Warns Most Kids Won't Know a World Without AI Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Looking closer, the stock has also trailed behind the Health Care Select Sector SPDR Fund's (XLV) 10.8% decline over the past 52 weeks and a marginal fall year-to-date. Thermo Fisher released its Q2 2025 earnings on July 23, and its shares popped 9.1%. It reported revenue of $10.85 billion, a 3% year-over-year increase (with 2% organic growth). Adjusted EPS was $5.36, compared to $5.37 in the prior year, while adjusted operating income rose to $2.38 billion from $2.35 billion in the year-ago quarter. Thermo Fisher also highlighted the launch of next-generation instruments, including Orbitrap Astral Zoom, Orbitrap Excedion Pro, and the Krios 5 Cryo-TEM, as well as an expanded DynaDrive single-use bioreactor portfolio. For the fiscal year ending in December 2025, analysts expect TMO's adjusted EPS to grow 3% year-over-year to $22.52. The company's earnings surprise history is promising. It topped the consensus estimates in the last four quarters. Among the 26 analysts covering the stock, the consensus rating is a 'Strong Buy.' That's based on 18 'Strong Buy' ratings, three 'Moderate Buys,' and five 'Holds.' This configuration has been stable over the past months. On July 28, UBS analyst Dan Leonard downgraded Thermo Fisher to 'Neutral' from 'Buy,' cutting the price target to $460 from $500, citing concerns that persistent headwinds could weigh on life sciences R&D, which accounts for about half of the company's sales. UBS also forecast 2026 organic sales growth of 4%, 200 basis points below consensus, and reduced its longer-term outlook. TMO's mean price target of $553.60 implies a modest potential upside of 13.2% from the current price levels. Similarly, the Street-high price target of $650 indicates that the stock could soar by 32.9%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
